Figure 5
From: Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy
GRh2 treatment decreases β-catenin and increases autophagy in HCC cells.
(A,B) GRh2 treatment dose-dependently decreases β-catenin and dose-dependently upregulated autophagy-related proteins Beclin, Atg7 and increased the ratio of LC3 II to LC3 I, by quantification (A) and by representative Western blots (B) in HepG2 cells. (C) GRh2 treatment dose-dependently decreases β-catenin transcripts in HepG2 cells. (D,E) GRh2 treatment dose-dependently decreases β-catenin and dose-dependently upregulated autophagy-related proteins Beclin, Atg7 and increased the ratio of LC3 II to LC3 I, shown by quantification (E) and by representative Western blots (F) in Huh7 cells. (G) GRh2 treatment dose-dependently decreases β-catenin transcripts in Huh7 cells. *p < 0.05. N = 5.
